tiprankstipranks
Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street
The Fly

Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street

Lake Street analyst Brooks O’Neil notes that Stryker (SYK) announced a definitive agreement for the sale of its U.S. spinal implants business and plans to sell its related international business. Alphatec (ATEC) is likely to benefit from ongoing spine industry disruption, contends the analyst, who believes an inflection to profitability will “make a big difference for many investors” and affirms a Buy rating and our $18 price target on Alphatec shares.

Invest with Confidence:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App